Belite Bio announces successful Phase 1 clinical trials of AMD drug
Category: #health  By Saipriya Iyer  Date: 2020-07-21
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Belite Bio announces successful Phase 1 clinical trials of AMD drug

San Diego-based clinical stage biopharmaceutical firm, Belite Bio has recently revealed positive data from Phase 1 trials conducted in Australia and the U.S. on LBS-008, an oral small molecule RBP4 (Retinol Binding Protein 4) specific antagonist that is targeted towards treating atrophic Dry AMD (age-related macular degeneration) and its inherited juvenile form, Stargardt disease.

Sources close to the development state that around 83 subjects took part in the trials, with LBS-008 being administered either as a single or repetitive dose for two weeks. Following the clinical trials, it was established that doses of LBS-008 were proven to be well tolerated, with LBS-008's PK / PD profile supporting daily oral administration. In addition to this, LBS-008 attained possible clinical-level target engagement.

Dr. Konstantin Petrukhin, Prof. of Ophthalmic Science, Columbia University, said that the positive results from LBS-008 trial is given to an effective collaboration between Belite Bio, NIH, and the Columbia University. We are thrilled to see LBS-008 enter the next clinical phase and expect it to pause the progression of Stargardt disease and Dry AMD.

Charles Cywin, Program Director, National Institute of Neurological Disorders & Stroke, NIH, said that Dry AMD is one of the common causes of blindness and currently has no treatment. The LBS-008 clinical trial’s transition to Phase 2 comes as an example of how NIH BPN visions to help researchers transform promising ideas into effective therapies for addressing some of the most complex neurological disorders.  

As per Dr. Tom Lin, Chief Executive Officer, Belite Bio, their firm is pleased to have accomplished this key milestone along with the support of NIH BPN. The company appreciates the support of the BPN team for driving the development of LBS-008 in Phase 1 which has successfully demonstrated promising results.

Source Credit: https://www.prnewswire.com/news-releases/belite-bio-announces-positive-results-from-phase-1-clinical-trials-of-lbs-008-301095197.html



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...